Authors
Julius J Grunow, Katja Reiher, Niklas M Carbon, Lilian Jo Engelhardt, Knut Mai, Susanne Koch, Joerg C Schefold, Werner Z’Graggen, Stefan J Schaller, Jens Fielitz, Joachim Spranger, Steffen Weber-Carstens, Tobias Wollersheim
Publication date
2022/8/3
Journal
Critical care
Volume
26
Issue
1
Pages
237
Publisher
BioMed Central
Description
Background
The objective was to investigate the role of gene expression and plasma levels of the muscular protein myostatin in intensive care unit-acquired weakness (ICUAW). This was performed to evaluate a potential clinical and/or pathophysiological rationale of therapeutic myostatin inhibition.
Methods
A retrospective analysis from pooled data of two prospective studies to assess the dynamics of myostatin plasma concentrations (day 4, 8 and 14) and myostatin gene (MSTN) expression levels in skeletal muscle (day 15) was performed. Associations of myostatin to clinical and electrophysiological outcomes, muscular metabolism and muscular atrophy pathways were investigated.
Results
MSTN gene expression (median [IQR] fold change: 1.00 [0.68–1.54] vs. 0.26 [0.11–0.80]; p = 0.004) and myostatin plasma concentrations were significantly reduced in all critically ill patients when compared to healthy controls …
Total citations
20243
Scholar articles
JJ Grunow, K Reiher, NM Carbon, LJ Engelhardt, K Mai… - Critical care, 2022